BRILINTA (Tricagrelor) is an antiplatelet drug that works by blocking platelets from sticking together and prevents them from forming harmful clots and keeps blood flowing smoothly in your body. It is the first and the only antiplatelet (OAP) in a chemical class.
BRILINTA is indicated to reduce the risk of cardiovascular death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction.
It is indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of ticagrelor was established in a population with type 2 diabetes.
BRILINTA is a P2Y12 platelet inhibitor indicated to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI). BRILINTA also reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS.
Available in Strengths of 60mg & 60 mg